ASTRO supports US Nuclear Regulatory Commission final rule

August 18, 2017

ARLINGTON, Va., August 18, 2017 - The American Society for Radiation Oncology (ASTRO) applauds the United States Nuclear Regulatory Commission (NRC) for yesterday's announcement of a final rule that updates the definition of medical events for permanent implant brachytherapy and protects patients' access to this treatment. The modifications to Part 35, Medical Use of Byproduct Material, of Title 10, the Code of Federal Regulations, are consistent with ASTRO recommendations and follow more than a decade of ASTRO members and staff working with the NRC and the Advisory Committee on the Medical Use of Isotopes (ACMUI).

Under the final rule, states authorized by the NRC to regulate radioactive materials, such as those used in brachytherapy, must maintain a consistent program for reporting medical events for permanent implant brachytherapy and strive to avoid conflicts, duplications and gaps in reporting. The final rule makes several key changes to how the NRC defines medical events for permanent implant brachytherapy, most notably adopting activity-based rather than dose-based criteria for event reporting. The NRC states that the use of a dose-based definition "captures insignificant events as medical events," echoing concerns raised by ASTRO about the incorrect characterization of medically acceptable implants, such as brachytherapy seeds, as medical events. The current rule will become official 180 days after its publication in the federal register.

"ASTRO commends the NRC for moving forward with changes that maintain its rigorous standards of quality and safety while demonstrating a flexibility to meet modern medical needs," said ASTRO Chair David C. Beyer, MD, FASTRO. "As the number of patients seeking permanent implant brachytherapy continues to grow, so does the need for physicians and practices to provide this treatment. By adopting more accurate and more appropriate criteria for reporting brachytherapy-related medical events, the NRC has removed a barrier for clinicians looking to treat patients with this established therapeutic option. This step is likely to both protect and increase access to cancer care for a large number of patients."
-end-
ABOUT ASTRO

ASTRO is the premier radiation oncology society in the world, with nearly 10,000 members who are physicians, nurses, biologists, physicists, radiation therapists, dosimetrists and other health care professionals who specialize in treating patients with radiation therapies. As the leading organization in radiation oncology, the Society is dedicated to improving patient care through professional education and training, support for clinical practice and health policy standards, advancement of science and research, and advocacy. ASTRO publishes three medical journals, International Journal of Radiation Oncology * Biology * Physics, Practical Radiation Oncology and Advances in Radiation Oncology; developed and maintains an extensive patient website, RT Answers; and created the Radiation Oncology Institute, a non-profit foundation to support research and education efforts around the world that enhance and confirm the critical role of radiation therapy in improving cancer treatment. To learn more about ASTRO, visit http://www.astro.org.

American Society for Radiation Oncology

Related Brachytherapy Articles from Brightsurf:

Outcomes of salvage low dose RT brachytherapy after EBRT for prostate cancer
Researchers involved in the phase II NRG Oncology RTOG 0526 trial studying low dose rate (LDR) prostate brachytherapy (BT) following local recurrence (LR) after external beam radiotherapy (EBRT) for patients with low-to-intermediate risk prostate cancer reported late Grade 3 gastrointestinal and genitourinary adverse events (AEs) occurring in 14% of trial participants.

Brachytherapy proves effective in treating skin cancer
The use of high-dose-rate brachytherapy to treat elderly patients with common skin cancers offers excellent cure rates and cosmetic outcomes, according to a new study.

Aesthetics of skin cancer therapy may vary by treatment type
In a meta-analysis of 58 studies, a study led by Penn State compared four types of skin cancer treatments and found that while all four had similar recurrence rates a year after treatment, a form of radiation called brachytherapy and a type of surgery called Mohs micrographic surgery had better cosmetic results.

Single dose of targeted radiotherapy is safe and effective for prostate cancer
A single high dose of radiation that can be delivered directly to the tumor within a few minutes is a safe and effective technique for treating men with low-risk prostate cancer, according to a study presented at the ESTRO 38 conference.

Benefit of LDR brachytherapy in patients with early-stage prostate cancer is still unclear
Even eleven years after the first benefit assessment, the evidence base remains inadequate.

PROs indicate brachytherapy alone is the superior treatment
Patient-Reported Outcomes (PROs) from the NRG Oncology trial RTOG 0232 comparing a combined treatment of external beam therapy and brachytherapy (EBT+B) to transperineal interstitial permanent brachytherapy (B) alone indicate a significantly different clinician and patient-reported late toxicity profile between arms despite similarities in progression-free survival results.

Brachytherapy for cervical cancer does not increase the risk of ureteral stricture
New research presented at the ESTRO 37 conference from two large international trials, shows that intracavitary and interstitial brachytherapy is safe and does not increase the risk of ureteral stricture in cervical cancer patients.

VCU scientists seek to perfect calculations for comparing cervical cancer radiation doses
Research from VCU Massey Cancer Center has found that one of the standard practices for comparing cervical cancer radiation therapy treatments may be misleading, and the use of an alternative mathematical formula could be used to more effectively predict and potentially improve outcomes for patients.

A gold-standard cancer treatment is in decline, and money may be why
Offering brachytherapy for locally advanced cervical cancer ends up costing hospitals money, potentially explaining its declining use even though it's considered the most effective treatment.

Cleveland Clinic leads development of new guidelines for radiation in breast cancer
Cleveland Clinic researcher Chirag Shah, M.D., led the development of updated guidelines for the appropriate and safe utilization of accelerated partial-breast irradiation (APBI).

Read More: Brachytherapy News and Brachytherapy Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.